This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kurland, E. S. Articles by Bilezikian, J. P. Search for Related Content PubMed PubMed Citation Articles by Kurland, E. S. Articles by Bilezikian, J. P.

Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers¹

Departments of Medicine (E.S.K., F.C., R.L., J.P.B.) and Pharmacology (J.P.B.) and the Irving Center for Clinical Research (D.J.M.), Columbia University College of Physicians and Surgeons, New York, New York 10032; Maine Center for Osteoporosis Research, St. Joseph Hospital (C.J.R.), Bangor, Maine 04401; and Regional Bone Center, Helen Hayes Hospital (F.C., R.L.), West Haverstraw, New York 10993

Address all correspondence and requests for reprints to: Etah S. Kurland, M.D., Department of Medicine, Columbia University College of Physicians Surgeons, 630 West 168th Street; New York, New York 10032. E-mail: esk11{at}columbia.edu

Osteoporosis in men poses a unique therapeutic challenge. Clinical studies have focused largely on the more prevalent problem of postmenopausal osteoporosis, with few gender-specific studies exploring treatment options in men. Idiopathic osteoporosis in middle-aged men presents an additional dilemma, because in the majority of patients it is a low bone turnover state for which there are currently no available anabolic agents.

We conducted an 18-month randomized, double blind, placebo-controlled trial of 23 men with idiopathic osteoporosis, 30–68 yr old (mean age ± SEM, 50 ± 1.9 yr). All patients received 1500 mg calcium and 400 IU vitamin D daily. Ten patients were randomized to receive 400 IU PTH-(1–34), and 13 patients received vehicle, administered by daily sc injection. Serum and urinary biochemistries, including markers of bone turnover were measured every 3 months. Bone densitometry of the lumbar spine, hip, and radius was performed every 6 months.

PTH-(1–34) was associated with a marked 13.5% increase in bone mass at the lumbar spine, whereas that in the control group did not change (P < 0.001). The mean lumbar spine T-score improved from -3.5 ± 0.2 to -2.4 ± 0.4. Femoral neck bone mineral density in the PTH-treated group increased 2.9% (P < 0.05). The 1/3 site of the distal radius showed no change from baseline in the PTH-treated group. There were no significant changes in serum calcium concentration, 24-h urinary calcium excretion, or 1,25-dihydroxyvitamin D in either group. All markers of bone turnover increased in the PTH-treated patients, with the greatest changes in serum osteocalcin and urinary N-telopeptide (230% and 375% above baseline by 12 months, respectively; P < 0.001). Free pyridinoline and markers of bone formation that showed little correlation with each other at baseline, became highly correlated in the PTH-treated group (r = 0.1; P = 0.29 at baseline; to r = 0.7; P < 0.0001 at 18 months), a pattern absent in the control patients. The best predictor of the lumbar spine response to PTH at 18 months was the combination of pyridinoline at baseline and osteocalcin at 3 months (70% of the variance).

PTH is a potent stimulator of skeletal dynamics in men with idiopathic, low turnover osteoporosis; is associated with substantial increases in lumbar spine and hip bone density; and may prove to be an efficacious anabolic agent in men with this disorder.

This article has been cited by other articles:

				K. A. Hegge, A. S. Fornoff, S. L. Gutierres, and S. L. Haack New Therapies for Osteoporosis Journal of Pharmacy Practice, February 1, 2009; 22(1): 53 - 64. [Abstract] [PDF]

				P. D. Miller, P. D. Delmas, R. Lindsay, N. B. Watts, M. Luckey, J. Adachi, K. Saag, S. L. Greenspan, E. Seeman, S. Boonen, et al. Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3785 - 3793. [Abstract] [Full Text] [PDF]

				T. Kawano, N. Troiano, D. J. Adams, J. Jun Wu, B.-h. Sun, and K. Insogna The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout Mice Endocrinology, August 1, 2008; 149(8): 4009 - 4015. [Abstract] [Full Text] [PDF]

				S. Khosla, S. Amin, and E. Orwoll Osteoporosis in Men Endocr. Rev., June 1, 2008; 29(4): 441 - 464. [Abstract] [Full Text] [PDF]

				S. Sharma, M. Fraser, F. Lovell, A. Reece, and A. R. McLellan Characteristics of males over 50 years who present with a fracture: EPIDEMIOLOGY AND UNDERLYING RISK FACTORS J Bone Joint Surg Br, January 1, 2008; 90-B(1): 72 - 77. [Abstract] [Full Text] [PDF]

				D. M. Antoniucci, D. E. Sellmeyer, J. P. Bilezikian, L. Palermo, K. E. Ensrud, S. L. Greenspan, and D. M. Black Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 942 - 947. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, B. Z. Leder, S.-A. M. Burnett, J. J. Wyland, H. Lee, A. V. de la Paz, K. Gibson, and R. M. Neer Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2882 - 2887. [Abstract] [Full Text] [PDF]

				A. Cranney, A. Papaioannou, N. Zytaruk, D. Hanley, J. Adachi, D. Goltzman, T. Murray, A. Hodsman, and for the Clinical Guidelines Committee of Osteoporo Parathyroid hormone for the treatment of osteoporosis: a systematic review. Can. Med. Assoc. J., July 4, 2006; 175(1): 52 - 59. [Abstract] [Full Text] [PDF]

				V. J. Wright Osteoporosis in Men J. Am. Acad. Ortho. Surg., June 1, 2006; 14(6): 347 - 353. [Abstract] [Full Text] [PDF]

				D. C. Bauer, P. Garnero, J. P. Bilezikian, S. L. Greenspan, K. E. Ensrud, C. J. Rosen, L. Palermo, D. M. Black, and for the PTH and Alendronate (PaTH) Research Group Short-Term Changes in Bone Turnover Markers and Bone Mineral Density Response to Parathyroid Hormone in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1370 - 1375. [Abstract] [Full Text] [PDF]

				F. Cosman, J. Nieves, M. Zion, L. Woelfert, M. Luckey, and R. Lindsay Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate N. Engl. J. Med., August 11, 2005; 353(6): 566 - 575. [Abstract] [Full Text] [PDF]

				A. B. Hodsman, D. C. Bauer, D. W. Dempster, L. Dian, D. A. Hanley, S. T. Harris, D. L. Kendler, M. R. McClung, P. D. Miller, W. P. Olszynski, et al. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use Endocr. Rev., August 1, 2005; 26(5): 688 - 703. [Abstract] [Full Text] [PDF]

				H. Dobnig, A. Sipos, Y. Jiang, A. Fahrleitner-Pammer, L.-G. Ste-Marie, J. C. Gallagher, I. Pavo, J. Wang, and E. F. Eriksen Early Changes in Biochemical Markers of Bone Formation Correlate with Improvements in Bone Structure during Teriparatide Therapy J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3970 - 3977. [Abstract] [Full Text] [PDF]

				B. Weinstock-Guttman, E. Gallagher, M. Baier, L. Green, J. Feichter, K. Patrick, C. Miller, K. Wrest, and M. Ramanathan Risk of bone loss in men with multiple sclerosis Multiple Sclerosis, April 1, 2004; 10(2): 170 - 175. [Abstract] [PDF]

				G. R. Madore, P. J. Sherman, and J. M. Lane Parathyroid Hormone J. Am. Acad. Ortho. Surg., March 1, 2004; 12(2): 67 - 71. [Full Text] [PDF]

				R.M. Francis, S.P. Baillie, A.J. Chuck, P.R. Crook, N. Dunn, J.N. Fordham, C. Kelly, and A. Rodgers Acute and long-term management of patients with vertebral fractures QJM, February 1, 2004; 97(2): 63 - 74. [Abstract] [Full Text] [PDF]

				K. A Cappuzzo and J. C Delafuente Teriparatide for Severe Osteoporosis Ann. Pharmacother., February 1, 2004; 38(2): 294 - 302. [Abstract] [Full Text] [PDF]

				B. Ettinger, G. T. Ray, A. R. Pressman, and O. Gluck Limb Fractures in Elderly Men as Indicators of Subsequent Fracture Risk Arch Intern Med, December 8, 2003; 163(22): 2741 - 2747. [Abstract] [Full Text] [PDF]

				R. A. Adler and M. C. Hochberg Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs Arch Intern Med, November 24, 2003; 163(21): 2619 - 2624. [Abstract] [Full Text] [PDF]

				D. M. Black, S. L. Greenspan, K. E. Ensrud, L. Palermo, J. A. McGowan, T. F. Lang, P. Garnero, M. L. Bouxsein, J. P. Bilezikian, C. J. Rosen, et al. The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis N. Engl. J. Med., September 25, 2003; 349(13): 1207 - 1215. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, A. Hayes, J. L. Hunzelman, J. J. Wyland, H. Lee, and R. M. Neer The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis N. Engl. J. Med., September 25, 2003; 349(13): 1216 - 1226. [Abstract] [Full Text] [PDF]

				K. K. Winer, C. W. Ko, J. C. Reynolds, K. Dowdy, M. Keil, D. Peterson, L. H. Gerber, C. McGarvey, and G. B. Cutler Jr. Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1-34) Versus Calcitriol and Calcium J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4214 - 4220. [Abstract] [Full Text] [PDF]

				I. Ahmed, D. Gesty-Palmer, M. K. Drezner, and L. M. Luttrell Transactivation of the Epidermal Growth Factor Receptor Mediates Parathyroid Hormone and Prostaglandin F2{alpha}-Stimulated Mitogen-Activated Protein Kinase Activation in Cultured Transgenic Murine Osteoblasts Mol. Endocrinol., August 1, 2003; 17(8): 1607 - 1621. [Abstract] [Full Text] [PDF]

				F. K. W. Chan, S.-C. Tiu, K.-L. Choi, C.-H. Choi, A. P. S. Kong, and C.-C. Shek Increased Bone Mineral Density in Patients with Chronic Hypoparathyroidism J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3155 - 3159. [Abstract] [Full Text] [PDF]

				J. P. Brown and R. G. Josse Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38. [Abstract] [Full Text] [PDF]

				B. M. Misof, P. Roschger, F. Cosman, E. S. Kurland, W. Tesch, P. Messmer, D. W. Dempster, J. Nieves, E. Shane, P. Fratzl, et al. Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1150 - 1156. [Abstract] [Full Text] [PDF]

				M. J. Horwitz, M. B. Tedesco, C. Gundberg, A. Garcia-Ocana, and A. F. Stewart Short-Term, High-Dose Parathyroid Hormone-Related Protein as a Skeletal Anabolic Agent for the Treatment of Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 569 - 575. [Abstract] [Full Text] [PDF]

				E Dogan and C Posaci Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women Postgrad. Med. J., December 1, 2002; 78(926): 727 - 731. [Abstract] [Full Text] [PDF]

				J. P. Brown and R. G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34. [Abstract] [Full Text] [PDF]

				C. Crandall Parathyroid Hormone for Treatment of Osteoporosis Arch Intern Med, November 11, 2002; 162(20): 2297 - 2309. [Abstract] [Full Text] [PDF]

				P. Gillberg, H. Mallmin, M. Petren-Mallmin, S. Ljunghall, and A. G. Nilsson Two Years of Treatment with Recombinant Human Growth Hormone Increases Bone Mineral Density in Men with Idiopathic Osteoporosis J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4900 - 4906. [Abstract] [Full Text] [PDF]

				J. Rubin, C. L. Ackert-Bicknell, L. Zhu, X. Fan, T. C. Murphy, M. S. Nanes, R. Marcus, L. Holloway, W. G. Beamer, and C. J. Rosen IGF-I Regulates Osteoprotegerin (OPG) and Receptor Activator of Nuclear Factor-{kappa}B Ligand in Vitro and OPG in Vivo J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4273 - 4279. [Abstract] [Full Text] [PDF]

				S P Tuck and R M Francis Osteoporosis Postgrad. Med. J., September 1, 2002; 78(923): 526 - 532. [Abstract] [Full Text] [PDF]

				A. J. Kahn and B. Halloran Dehydroepiandrosterone Supplementation and Bone Turnover in Middle-Aged to Elderly Men J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1544 - 1549. [Abstract] [Full Text] [PDF]

				J. Reeve Recombinant human parathyroid hormone BMJ, February 23, 2002; 324(7335): 435 - 436. [Full Text] [PDF]

				E. Canalis and A. Giustina Glucocorticoid-Induced Osteoporosis: Summary of a Workshop J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5681 - 5685. [Full Text] [PDF]

				C. J. Rosen and J. P. Bilezikian Anabolic Therapy for Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 957 - 964. [Abstract] [Full Text]

				G. M Prelevic Osteoporosis in men J R Soc Med, January 12, 2001; 94(12): 620 - 623. [Full Text] [PDF]